NCT06033586 (THRIVE) is a Phase 3 clinical trial of Open-label rusfertide in Polycythemia Vera, sponsored by Protagonist Therapeutics, Inc..

Who is sponsoring NCT06033586?

NCT06033586 is sponsored by Protagonist Therapeutics, Inc..

What drugs are being tested in NCT06033586?

Interventions in NCT06033586: Open-label rusfertide.

What condition does NCT06033586 study?

NCT06033586 studies Polycythemia Vera.

Is NCT06033586 still recruiting?

NCT06033586 is currently active, enrolled. Last updated 6 August 2025.

Last reviewed 2025-08-06 · How we verify

NCT06033586: THRIVE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera

Active, enrolled Phase 3 Last updated 6 August 2025

What this trial tests

Phase 3 trial testing Open-label rusfertide in Polycythemia Vera in 46 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

22 January 2024

Primary endpoint
1 April 2026

1 April 2027

Quick facts

Lead sponsor	Protagonist Therapeutics, Inc.
Phase	Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	46
Start date	22 January 2024
Primary completion	1 April 2026
Estimated completion	1 April 2027
Sites	1 location across United States

Drugs / interventions tested

Open-label rusfertide — full drug profile →

Conditions studied

Polycythemia Vera — all drugs for Polycythemia Vera →

Sponsor

Protagonist Therapeutics, Inc. — full company profile →

Who can join

18 and older, any sex, with Polycythemia Vera. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to assess long-term safety and efficacy of rusfertide in subjects with polycythemia vera. Subjects who complete dosing with rusfertide until the end-of-treatment visit of a Phase 2 rusfertide study and meet the inclusion/exclusion criteria for this study, are eligible to participate in this open-label study and continue treatment with rusfertide.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.
Xiao W, Jiang W, Chen Z, Huang Y, et al · · 2025 · cited 144× · PMID 40038239 · DOI 10.1038/s41392-024-02107-5
Modern and multidisciplinary care in polycythemia vera.
Palandri F, Sartor C, Pileri A, Addimanda O, et al · · 2026 · PMID 41999414 · DOI 10.1007/s00277-026-06970-w
Advances in polycythemia vera treatment with targeted therapies and clinical trials.
Hassanien D, AlYafei RA, Metwally OH, Alremawi I, et al · · 2025 · PMID 41144126 · DOI 10.1007/s12672-025-03703-9
EHA2024 Hybrid Congress
· 2024

Verify or expand the search:

Other recruiting trials for Polycythemia Vera

Currently open trials in the same condition.

NCT07203768 — A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes · recruiting
NCT07362225 — MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel · recruiting
NCT06661915 — A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) · Phase 2 · recruiting
NCT06752941 — LOW-PV Continuation · recruiting
NCT06734637 — Efficacy and Safety of Peginterferon in ET and PV. · NA · recruiting

Other Protagonist Therapeutics, Inc. trials

Trials by the same sponsor.

NCT07153146 — Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects. · Phase 1 · recruiting
NCT04819620 — Pharmacokinetics of PN-232 in Healthy Volunteers · Phase 1 · completed
NCT04767802 — PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit · Phase 2 · completed
NCT04621630 — Pharmacokinetics of PN-235 in Healthy Volunteers · Phase 1 · completed
NCT04516382 — Pharmacokinetics and Pharmacodynamics of Different PTG-300 Regimens in Healthy Volunteers · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06033586 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Protagonist Therapeutics, Inc.
Last refreshed: 6 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06033586.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing